TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00914940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Fludarabine will be administered in a dose of 25 mg/m2/day IV over approximately 30 minutes for 5 consecutive days (day -6 to -2). The total dose of fludarabine will be 125 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be administered beginning on day -1 at a dose of 0.03 mg/kg/day by continuous IV infusion.~For the first cohort of 35 patients, if there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus should then be tapered at the rate of approximately 5% of the day 50 dose each week for liquid, and 20% of the day 50 dose per month for capsules.~In the second cohort of 25 patients if there is no evidence of grade II GVHD on or prior to day 30, tacrolimus should then be tapered at the rate of approximately 8% of the day 30 dose each week for liquid, and 33% of the day 30 dose per month for capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa will be administered in a dose of 5 mg/kg/day (adjusted body weight) IV over approximately 4 hours for 2 consecutive days (day -6 and day -5).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation (TBI)
Description: TBI will be given as 165 cGy fractions twice per day x 4 days - total dose 1320cGy (days -10 to -7).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Affinity Cell Sorting
Description: Device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Patient will undergo a PBSC transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Patients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T Cell-Depleted Hematopoietic Stem Cell Transplantation
Description: Patients who are eligible will receive a T Cell-Depleted Hematopoietic Stem Cell Transplantation
Study: NCT01197846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: quetiapine 300 mg or 600 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00234533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin (rDNA origin)
Description: Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.
Study: NCT03784677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPV6 Calcium Channel Inhibitor SOR-C13
Description: Given IV
Study: NCT01712802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Denture Adhesives: Cream
Description: Using Polident as denture adhesive to compare its effect on PRO and subjective outcomes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Denture Adhesives: Powder
Description: Using Poligrip powder as denture adhesive to compare its effect on PRO and subjective outcomes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: work as control for Denture Adhesives: Cream and Powder
Study: NCT01824355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ninja 3 PLUS Investigational BG Monitoring System
Description: Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Ninja 3 PLUS Investigational BG Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to a reference laboratory glucose method.
Study: NCT02097030

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: filcon II 3
Description: Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
Study: NCT02327923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Inj. Bupivacaine 0.25% 10 ml will be infiltrated at incision site after closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Inj. Bupivacaine 0.25% 10 ml will be infiltrated at incision site after closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Inj tramadol 50 mg IV will be given on SOS basis in ward.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Inj tramadol 50 mg IV will be given on SOS basis in ward.
Study: NCT02531048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 laser stimulations for each site on the upper limbs
Description: 20 laser stimulations for each site : back of the hands and arms front face

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser stimulations on face and neck
Description: 15 lasers stimulations for each site : mandibular areas and areas below the ears.
Study: NCT03119402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic Reading Training
Description: RRT is a computerized reading training program designed for Italian students with dyslexia. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Rhythmic Reading Training
Description: RRT is a computerized reading training program designed for Italian students with dyslexia. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS (transcranial direct current stimulation) is a noninvasive weak-current brain stimulation technique that can facilitate (anodal electrode) or inhibit (cathodal electrode) cortical activity, thus offering exciting possibilities for the enhancement and treatment of impaired cognitive abilities.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS (transcranial direct current stimulation) is a noninvasive weak-current brain stimulation technique that can facilitate (anodal electrode) or inhibit (cathodal electrode) cortical activity, thus offering exciting possibilities for the enhancement and treatment of impaired cognitive abilities.
Study: NCT00054457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study: NCT00101296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03371849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast and levocetirizine FDC
Description: HCP1102
Study: NCT00054457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT02986529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GV-971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV-971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV-971

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT04305743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA 100 UNT
Description: Intradetrusor onabotulinumtoxin A is administered cystoscopically with 100 unit dose given as either 5 or 20 injections in a single procedure based on the arm the participant is randomized into.
Study: NCT03371849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast and levocetirizine FDC
Description: HCP1102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singulair + xyzal
Description: HGP0813 + HGP1408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Singulair + xyzal
Description: HGP0813 + HGP1408
Study: NCT02272608

Intervention type: OTHER
Intervention: Evaluation of Sleep Apnea Related Inflammation with CRP, ESR and Neutrophil toLymphocyte Ratio
Description: CRP, ESR and Neutrophil toLymphocyte Ratio values of sleep apnea patients were evaluated with respect to apnea- hypopnea scores.

Intervention type: OTHER
Intervention: Evaluation of Sleep Apnea Related Inflammation with CRP, ESR and Neutrophil toLymphocyte Ratio
Description: CRP, ESR and Neutrophil toLymphocyte Ratio values of sleep apnea patients were evaluated with respect to apnea- hypopnea scores.

Intervention type: OTHER
Intervention: Evaluation of Sleep Apnea Related Inflammation with CRP, ESR and Neutrophil toLymphocyte Ratio
Description: CRP, ESR and Neutrophil toLymphocyte Ratio values of sleep apnea patients were evaluated with respect to apnea- hypopnea scores.

Intervention type: OTHER
Intervention: Evaluation of Sleep Apnea Related Inflammation with CRP, ESR and Neutrophil toLymphocyte Ratio
Description: CRP, ESR and Neutrophil toLymphocyte Ratio values of sleep apnea patients were evaluated with respect to apnea- hypopnea scores.
Study: NCT01345253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: 10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
Study: NCT03701022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1210
Description: SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes. Apatinib oral administration, 500mg per day.
Study: NCT01309802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: onabotulinum toxin type-A
Description: up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
Study: NCT01560962

Intervention type: DRUG
Group type: OTHER
Intervention: povidone iodine
Description: over the counter (OTC) 5% povidone iodine (PI)

Intervention type: DRUG
Group type: OTHER
Intervention: povidone iodine
Description: over the counter (OTC) 5% povidone iodine (PI)

Intervention type: DRUG
Group type: OTHER
Intervention: povidone iodine
Description: over the counter (OTC) 5% povidone iodine (PI)

Intervention type: DRUG
Group type: OTHER
Intervention: povidone iodine
Description: over the counter (OTC) 5% povidone iodine (PI)

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin

Intervention type: DRUG
Group type: OTHER
Intervention: tobramycin-dexmethasone

Intervention type: OTHER
Group type: OTHER
Intervention: warm soaked eyelid wash
Study: NCT04305743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 UNT
Description: Intradetrusor onabotulinumtoxin A is administered cystoscopically with 100 unit dose given as either 5 or 20 injections in a single procedure based on the arm the participant is randomized into.
Study: NCT02097030

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A
Description: Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
Study: NCT04779047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab 800 mg once.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Tocilizumab 800 mg once.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ Ritonavir
Description: Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Ivermectin 36 mg at day 1,3 and 6.
Study: NCT00110422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Tablets, Oral, 150 mg. titrated to 300 mg, once daily, 28 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Tablets, Oral, 12.5 mg. titrated to 25 mg, once daily, 28 weeks.
Study: NCT02962609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semielevated Side-lying Position-ESL
Description: The infants in the experimental group (n = 38) were held in the ESL position. In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infantswere held in the side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and their head and neck were held at the same level by the researcher; whereas, their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semielevated Supine Position
Description: The ESU position was applied to the infants in the control group (n=42). In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and they was laid in the supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
Study: NCT00542633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject™
Description: Dosage as individually required

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Human Insulin
Description: Dosage as individually required
Study: NCT01558960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVit Melphalan
Description: IVit injections of Melphalan
Study: NCT00267956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1275 63 mg
Description: The patients will receive 90 mg (or 63 mg after filtration) subcutaneous injection on Weeks 0, 1, 2, and 3; Placebo subcutaneous injection on Weeks 12 and 16.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CNTO 1275 63 mg
Description: The patients will receive 90 mg (or 63 mg after filtration) subcutaneous injection on Weeks 0, 1, 2, and 3; Placebo subcutaneous injection on Weeks 12 and 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The patients will receive placebo subcutaneous injection on Weeks 0, 1, 2, and 3; At weeks 12 and 16 the patients will receive CNTo1275 90 mg (or 63 mg after filtration) subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive placebo subcutaneous injection on Weeks 0, 1, 2, and 3; At weeks 12 and 16 the patients will receive CNTo1275 90 mg (or 63 mg after filtration) subcutaneous injection
Study: NCT01262794

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDP6038
Description: 100 mg/mL solution for injection, single dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection Single-dose
Study: NCT01495754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coffee
Description: Comparison of different amounts of coffee

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: coffee
Description: Comparison of different amounts of coffee

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: coffee
Description: Comparison of different amounts of coffee
Study: NCT02005484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 4 mg/kg initial dose, followed by 2 mg/kg
Study: NCT01844362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterine transplantation
Description: Transplantation of the uterus from live donor and IVF treatment.
Study: NCT04597047

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Capillary Collection & Testing
Description: Two (2) fingersticks will be performed on each subject and capillary blood tested in the LumiraDx SARS-CoV-2 Ab test

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Venous Draw & Testing
Description: One (1) Venous Draw (to include one (1) 6.0 mL EDTA tube and one (1) 3.5 mL serum separator tube) will be collected from each subject. Blood will be tested in the LumiraDx SARS-CoV-2 Ab test
Study: NCT01621087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safflower oil
Description: Liquid safflower oil and safflower oil polyunsaturated margarine
Study: NCT03034772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide-timolol
Description: Topical eye drop (active comparator) used twice daily for study duration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears
Description: Topical eye drop (placebo comparator) used twice daily for study duration
Study: NCT03933735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNB-383B
Description: Intravenous (IV) Injection
Study: NCT03026426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONEMO
Description: Participants will be offered a behavioral activation-based intervention delivered by an application for smartphones (CONEMO) oriented to encourage them to be more active and to incorporate more activities in participants' everyday life.~Nurses will train participants to use CONEMO, make phone calls when participants are non-adherent, and provide technical support when necessary. Nurses will be supervised by clinical psychologists.
Study: NCT02043002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET scan
Study: NCT04740762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The women in the intervention groups were administered a three-session intervention program in addition to the routine care they received.The program encompassed providing the women with an educational booklet, childbirth stories and childbirth videos that were created to reduce their fears of childbirth.The interviews were held a total of three times, in gestational weeks 28-30, 31-33 and 34-36. The duration of the intervention at each visit was 60-80 minutes. Depending on the woman's own preference, she was invited to visit the delivery room at the second or last session and meet the midwives there. The women who did not wish to go to the delivery room were alternatively provided with photographs of the delivery room so they could take a look. Again as part of the education program, the women were given the links to the selected childbirth videos and given the opportunity to watch them.
Study: NCT01445366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High volume post dilution hemodiafiltration
Description: The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flux hemodialysis
Description: The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
Study: NCT03194724

Intervention type: OTHER
Intervention: Vitamin A supplementation
Description: Bi annual vitamin A supplementation programme

Intervention type: OTHER
Intervention: Vitamin A supplementation
Description: Bi annual vitamin A supplementation programme
Study: NCT03741530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide Tablets
Description: Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard management for ICH
Description: Usual care and drug in hospital

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard management for ICH
Description: Usual care and drug in hospital